Pharmaceutical Research & Manufacturers of America v. Commissioner, Maine Department of Human Services

201 F.R.D. 12, 2001 U.S. Dist. LEXIS 7626, 2001 WL 637579
CourtDistrict Court, D. Maine
DecidedJune 8, 2001
DocketNo. CIV 00-157-B-H
StatusPublished
Cited by2 cases

This text of 201 F.R.D. 12 (Pharmaceutical Research & Manufacturers of America v. Commissioner, Maine Department of Human Services) is published on Counsel Stack Legal Research, covering District Court, D. Maine primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Pharmaceutical Research & Manufacturers of America v. Commissioner, Maine Department of Human Services, 201 F.R.D. 12, 2001 U.S. Dist. LEXIS 7626, 2001 WL 637579 (D. Me. 2001).

Opinion

ORDER ON EDWIN D. SCHINDLER’S MOTION TO INTERVENE

HORNBY, Chief Judge.

Edwin D. Schindler owns stock in three companies that are members of Pharmaceutical Research and Manufacturers of America (PhRMA). He wants to intervene in the lawsuit PhRMA has brought against the Commissioner of the Maine Department of Human Services challenging the lawfulness of Maine’s prescription drug pricing statutes. Schindler wants to make an argument that PhRMA does not: specifically, that federal patent law preempts the Maine statutes. I DENY Schindler’s motion to intervene under Fed.R.Civ.P. 241; PhRMA adequately represents its members’ shareholders’ interests.

I. Analysis

A. Intervention of Right

Under Fed R. Civ. P. Rule 24(a)(2), a person who wants to intervene in a lawsuit must

satisfy four conjunctive prerequisites: (1) a timely application for intervention; (2) a demonstrated interest relating to the property or transaction that forms the basis of the ongoing action; (3) a satisfactory showing that the disposition of the action threatens to create a practical impairment or impediment to its ability to protect that interest; and (4) a satisfactory showing that existing parties inadequately represent its interest.

Pub. Serv. Co. of N.H. v. Patch, 136 F.3d 197, 204 (1st Cir.1998). I address each of the four prerequisites in turn. I will assume, as the parties have assumed, that PhRMA is conducting the lawsuit to the satisfaction of its member companies. The question, therefore, is the same as if the three corporations in which Schindler owns stock were already individual plaintiffs in the lawsuit.

(1) Timeliness

Schindler seeks intervention only as to future proceedings in this Court. I conclude that his motion is timely as to future proceedings. To be clear, that means that the motion is untimely as to the preliminary injunction issues, which were fully briefed and argued orally. I issued a preliminary injunction, the First Circuit has now vacated it, and there is no good excuse for Schindler not to have moved to intervene earlier if preliminary injunction was his concern. (Schindler did submit an amicus curiae brief to the court of appeals.)

(2) Demonstrated Interest

Schindler’s interest in this lawsuit is financial. He asserts that if PhRMA loses, the value of his stock in three member corporations will go down. That is enough to meet standing requirements under the Constitution, A’ticle III. See Franchise Tax Bd. of Cal. v. Alcan Aluminium Ltd., 493 U.S. 331, 336-37, 110 S.Ct. 661, 107 L.Ed.2d 696 (1990) (parent corporations that were sole shareholders of subsidiary corporations have Article III standing to challenge taxes imposed on the subsidiaries because the taxes threatened the parents with actual financial injury by reducing their return on their investments in the subsidiaries). Is Article III standing enough to support intervention under Rule 24(a)? The First Circuit has not answered [14]*14the question. Other courts have stated that a shareholder’s ownership interest in a corporation is not sufficient to support the shareholder’s Rule 24 intervention in the corporation’s litigation. See Gould v. Alleco, Inc., 883 F.2d 281, 285 (4th Cir.1989) (“In a sense, every company’s stockholders ... have a stake in the outcome of any litigation involving the company, but this alone is insufficient to imbue them with the degree of ‘interest’ required for Rule 24(a) intervention.”) (dicta); Rigco, Inc. v. Rauscher Pierce Refsnes, Inc., 110 F.R.D. 180, 183-84 (N.D.Tex.1986) (a shareholder’s interest in the corporation’s cause of action is not a “direct, substantial, legally protectable interest” of the sort the Fifth Circuit required for Rule 24(a)(2) intervention).2 Since I conclude below that a shareholder’s motion for intervention ordinarily should founder because corporations adequately represent shareholder interests, I need not resolve the issue.

(3) Practical Impairment

If Schindler is correct that the outcome of this lawsuit will affect his stock’s value, there is no other way apparent to protect that interest except for this lawsuit.

(4) Adequacy of Representation

Schindler acknowledges that PhRMA has “thoroughly raised” dormant commerce clause and Medicaid preemption arguments (the arguments that I found convincing and that the First Circuit rejected). But he asserts that PhRMA does not adequately represent the interests of a shareholder like him, because it has not advanced his patent law preemption argument. (In essence, Schindler’s patent argument is that the Maine statutes seek to control the prices and conditions under which patented prescription drugs can be sold, that those controls conflict with federal patent law, and that the challenged statutes are therefore preempted.) He asserts that he, as a patent attorney, is “most qualified” to advance that argument.

Where an applicant for intervention has the same interest as a party, adequate representation is presumed. Daggett, 172 F.3d at 111. The Supreme Court has said that the burden of showing that representation may be inadequate “should be treated as minimal,” Trbovich v. United Mine Workers of Am., 404 U.S. 528, 538 n. 10, 92 S.Ct. 630, 30 L.Ed.2d 686 (1972), but the First Circuit has stated that the requirement is nonetheless “more than a paper tiger.” Patch, 136 F.3d at 207. An applicant for intervention must at least identify the inadequacy of representation. Daggett, 172 F.3d at 111, 114—15. What Schindler has identified is PhRMA’s failure to argue that federal patent law preempts Maine’s statutes. That is not enough.

First, where the applicant for intervention is a shareholder seeking to assert an interest in his corporation’s lawsuit, his ability to rebut the presumption that the corporation will adequately represent its shareholders’ interests is more circumscribed.3 In that situation the presumption can ordinarily be rebutted only if the shareholder shows the sort of corporate disloyalty or carelessness that would support a derivative action.4 The reasons for restricting shareholder interven[15]*15tion in lawsuits brought by corporations are the same as those for the rule that a shareholder does not acquire a personal cause of action for injuries to the corporation. Regarding the latter, the First Circuit has stated that

[t]he rule is a salutary one: if a shareholder, dissatisfied with the dealings entered into between his corporation and a third party, automatically possessed a personal right of action against the third party, then corporations would be paralyzed. They could rarely act except by unanimous consent.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

United States v. St. Paul Fire & Marine Insurance
239 F.R.D. 404 (W.D. Pennsylvania, 2006)

Cite This Page — Counsel Stack

Bluebook (online)
201 F.R.D. 12, 2001 U.S. Dist. LEXIS 7626, 2001 WL 637579, Counsel Stack Legal Research, https://law.counselstack.com/opinion/pharmaceutical-research-manufacturers-of-america-v-commissioner-maine-med-2001.